Home » Newsletters » BioWorld Science

BioWorld Science

July 13, 2018

View Archived Issues

Forcing tumor cells to grow up

Preventing bacterial invisibility cloak

Targeting rare cells has large benefits

New mouse models demonstrate the role of HERV-W-Env in type 1 diabetes

Novel surgically induced rat model of diabetic nephropathy

Endogenous lipids stabilize GPCRs

Targeted radiotherapy with labeled NM-600 synergistic with immunotherapy in cancer model

Senescent cells-caused physical dysfunction and decreased survival are reversible with senolytics

Aurigene begins phase I trial of oral RORgammaT inverse agonist AUR-101

Phase I trial of OncoNano's tumor imaging agent ONM-100 begins

Compass Therapeutics set to advance next-generation antibody-based therapeutics into clinic

Oral tecovirimat is a putative antiviral treatment of smallpox

CohBar starts first-in-human testing of CB-4211 for the treatment of NASH

GlaxoSmithKline, Astex Therapeutics describe NRF2 activators

Beta Therapeutics divulges new heparanase inhibitors

Astellas' phase I study of ASP-1948 in advanced solid tumors enrolling patients

Yale University develops novel SV2A radiotracer for PET imaging of synaptic density

Positive topline data presented from second pivotal phase III study of ZX-008 in Dravet Syndrome

Audentes Therapeutics presents phase I/II data on AT-132 for XLMTM

Ono Pharmaceutical initiates phase I study of ONO-5788

N-Acetyl-beta-D-glucosaminidase inhibitors identified at Janssen

Lilly presents IDH1 and IDH2 mutant inhibitors

Shenzhen Chipscreen Biosciences patents indoleamine 2,3-dioxygenase 1 inhibitors

Roche presents phase II data for olesoxime in patients with SMA

Recruitment open for phase IIa study of Nerofe for AML and MDS

Jiangsu Wanbang Biopharmaceutical cleared to begin clinical trials of SGLT2 inhibitor in China

FDA approves Opdivo + Yervoy for MSI-H or dMMR metastatic colorectal cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...